Å·ÖÞÒ©Æ·¹ÜÀí¾ÖÈËÓÃҩƷίԱ»á¶ÔÄá´ïÄá²¼ÐÂÊÊÓ¦Ö¢³Ö¿Ï¶¨Òâ¼û

·¢²¼Ê±¼ä£º2020-03-03 17:41:26 À´Ô´£º
  • Å·ÖÞÒ©Æ·¹ÜÀí¾ÖÈËÓÃҩƷίԱ»á¶ÔÄá´ïÄá²¼ÖÎÁÆÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡£¨SSc-ILD£©[1]³Ö¿Ï¶¨Òâ¼û
  • »ùÓÚSENSCIS®ÊÔÑéµÄÕýÏò½á¹û£¬Äá´ïÄá²¼×î½üÔÚÃÀ¹ú»ñÅú£¬×÷ΪÊ׸öÒ²ÊÇΨһһÖÖ¼õ»ºÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡»¼Õ߷ι¦ÄÜϽµËٶȵÄÁÆ·¨¡£[3]
  • Äá´ïÄá²¼ÒÑÔÚ70¶à¸ö¹ú¼Ò»ñÅúÓÃÓÚÖÎÁÆÌØ·¢ÐÔ·ÎÏËά»¯£¨IPF£©

µÂ¹úÒó¸ñº²2020Äê3ÔÂ3ÈÕ /ÃÀͨÉç/ -- ²ªÁÖ¸ñÒó¸ñº²½üÈÕÐû²¼£¬Å·ÖÞÒ©Æ·¹ÜÀí¾ÖÈËÓÃҩƷίԱ»á¶ÔÄá´ïÄá²¼ÖÎÁÆÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡»ñµÃÉÏÊÐÐí¿ÉµÄ½¨Òé³Ö¿Ï¶¨Òâ¼û¡£[1]2019Äê9Ô£¬ÃÀ¹úʳƷҩƷ¹ÜÀí¾Ö£¨FDA£©ÒÑÅú×¼Äá´ïÄá²¼×÷ΪÊ׸öÒ²ÊÇΨһһÖÖ¼õ»ºÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡£¨SSc-ILD£©³ÉÈË»¼Õ߷ι¦ÄÜϽµËٶȵÄÒ©Îï¡£

ϵͳÐÔÓ²»¯²¡£¨SSc£©ÓÖ³ÆÓ²Æ¤²¡£¬ÊÇÒ»ÖÖ»ÙÈÝÐÔ¡¢Ö²ÐÐÔºÍDZÔÚÖÂËÀÐԵĺ±¼û×ÔÉíÃâÒßÐÔ¼²²¡¡£[5£¬6£¬7]Æä»áÒýÆð¸÷ÖÖÆ÷¹ÙµÄñ£ºÛ£¨ÏËά»¯£©£¬°üÀ¨·Î¡¢ÐÄÔà¡¢Ïû»¯µÀºÍÉöÔ࣬ÇÒ¿ÉÄܳöÏÖΣ¼°ÉúÃüµÄ²¢·¢Ö¢¡£Ó²Æ¤²¡£¨SSc£©ÀÛ¼°·ÎÔàʱ£¬¿ÉÒýÆð¼äÖÊÐԷμ²²¡£¨ILD£©£¬³ÆÎªÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡£¨SSc-ILD£©¡£[2£¬8]¼äÖÊÐԷμ²²¡£¨ILD£©ÊÇӲƤ²¡£¨SSc£©µÄÖ÷ÒªÖÂËÀÔ­Òò£¬¼¸ºõռӲƤ²¡£¨SSc£©Ïà¹ØËÀÍöµÄ35%¡£[9]

¡°ÏµÍ³ÐÔÓ²»¯²¡Ïà¹Ø¼äÖÊÐԷμ²²¡£¨SSc-ILD£©ÊÇÒ»ÖÖ»áÓ°ÏìÉú»îµÄ¼²²¡¡£·ÎÏËά»¯Ò»µ©·¢Éú½«ÎÞ·¨Äæ×ª£¬Õ⽫¶Ô»¼ÕßµÄÉú»îºÍÈÕ³£»î¶¯Ôì³ÉÆÆ»µÐÔÓ°Ï족£¬²ªÁÖ¸ñÒó¸ñº²¹«Ë¾¸ß¼¶¸±×ܲüæÑ×Ö¢ÖÎÁÆÁìÓò¸ºÔðÈËPeter Fang˵£¬¡°ÎÒÃÇһֱŬÁ¦¸ÄÉÆ·ÎÏËά»¯»¼ÕßµÄÉú»î£¬Òò´Ë¶ÔίԱ»áµÄ¿Ï¶¨Òâ¼û¸Ðµ½ÐÀÕâ´ú±í×ÅÔÚ¼õ»ºÕâÖÖÓ°ÏìÉúÃüµÄº±¼ûµÄ¼²²¡½øÕ¹·½Ã棬ÓÖÍÆ¶¯ÏòǰÂõ³öÁËÖØÒªÒ»²½¡£¡±

¸Ã¿Ï¶¨Òâ¼ûÊÇ»ùÓÚSENSCIS®ÊÔÑéµÄ½á¹û£¬ËüÊÇÒ»ÏîIIIÆÚ¡¢Ë«Ã¤¡¢°²Î¿¼Á¶ÔÕÕÊÔÑé¡£Ö¼ÔÚÑо¿Äá´ïÄá²¼ÔÚϵͳÐÔÓ²»¯²¡£¨SSc-ILD£©»¼ÕßÖеÄÁÆÐ§ºÍ°²È«ÐÔ¡£[2]ÆäÖ÷ÒªÖÕµãÊÇ52ÖÜÆÚ¼äÆÀ¹ÀµÄÓÃÁ¦·Î»îÁ¿£¨FVC£©ÄêϽµÂÊ¡£»¼Õß³ÖÐø½ÓÊÜÑо¿ÖÎÁÆÖÁÉÙ52ÖÜ»ò×î¶àÖÎÁÆ100ÖÜ¡£½á¹ûÏÔʾ°´52ÖÜÆÚ¼äµÄFVC²âÁ¿½á¹ûËùʾ£¬Ó밲ο¼ÁÏà±È£¬Äá´ïÄ᲼ʹ·Î¹¦ÄÜɥʧ·Å»ºÁË44%£¨41 mL/Ä꣩¡£[2]Äá´ïÄá²¼µÄ²»Á¼Ê¼þÌØÕ÷ÓëÔÚÌØ·¢ÐÔ·ÎÏËά»¯»¼ÕßÖй۲쵽µÄÏàËÆ£¬×î³£¼ûµÄ²»Á¼Ê¼þΪ¸¹Ðº¡£[2]

References

1 OFEV® positive opinion. European Medicines Agency. Available athttps://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ofev-ii-26_en.pdf. Last accessed February 2020.

2 Distler O, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Eng J Med. 2019; 380:2518-2528. Available at:http://dx.doi.org/10.1056/NEJMoa1903076. Last accessed February 2020.

3.Distler O, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Eng J Med. 2019; 380:2518-2528. Available at:http://dx.doi.org/10.1056/NEJMoa1903076. Last accessed October 2019.

5.Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685 1699.

6.Cottin V, et al. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res 2019;20:13.

7.Kowal-Bielecka O, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 2017;76:1327 1339.

8.Solomon JJ, et al. European Respiratory Update: Scleroderma lung disease. Eur. Respir. Rev. 2013; 22: 127, 6 19.

9.Tyndall AJ, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809 1815.


Ïà¹ØÈÈ´ÊËÑË÷£º
¹ØÓÚÎÒÃÇ ÁªÏµÎÒÃÇ ÈËÔ±²éѯ ÃâÔðÉùÃ÷ ÓÑÇéÁ´½Ó ¹óÖÝÍøLOGO ¹ã¸æ¿¯Àý ±¾Õ¾ÓòÃû °Ù¶ÈÐÂÎÅ